Andy Archuleta, DPM
Podiatry · Lodi
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 6 years
- California School of Podiatric Medicine, 2020
Offices
1 location · Lodi Podiatry Group · 3 clinicians in this group
Hospitals listed: Adventist Health Lodi Memorial · Sutter Amador Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Archuleta’s office at (209) 334-6664 to ask if they take your plan before you enroll.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Adventist Health Lodi MemorialLodi, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Adventist Health, which runs 28 hospitals in 3 statesPatients rate it 3 of 5 · 69% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.222, Oct 2024 – Sep 2025
- Sutter Amador HospitalJackson, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 77% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
See every measure and the patient survey for Adventist Health Lodi Memorial
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 0 better, 6 the same, 0 worse of 6 measures. Readmissions: 1 better, 3 the same, 2 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.222 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.19 (0.16 to 2.22) · 678 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.98 (0.59 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 203.28 (143.15 to 263.4) · 29 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.4 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 43 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.7 · 334 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.2 · 570 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.9 · 184 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.1 · 1,823 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.23 (0.02 to 0.45) · 4,072 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.08 to 0.49) · 4,094 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.18 (0.83 to 5.53) · 476 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.63 (0 to 3.34) · 81 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.46 (0.8 to 4.13) · 448 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.29 (0 to 17.86) · 79 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.88 (0.69 to 9.07) · 78 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.18 to 3.16) · 142 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.74 (0 to 1.53) · 3,347 cases | No different | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.368 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.655 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.506 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 27 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 450 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 47.3 · 381 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.2 · 604 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 20.1 · 661 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.9 · 188 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.6 (8.9 to 15.2) · 932 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 449 cases | No different | Jan 2024 – Dec 2024 |
What patients said (438 patients answered, 17% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 3 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 72% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 70% |
| Doctors "always" treated them with courtesy and respect | 79% |
| Patients who gave a rating of "9" or "10" (high) | 68% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 69% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Sutter Amador Hospital
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 3 the same, 0 worse of 3 measures. Readmissions: 1 better, 7 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.02 (0 to 2.09) · 180 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.6 to 1.5) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.4 · 47 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.6 · 139 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14 · 233 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10 · 81 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 803 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 1,886 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.05 to 0.47) · 1,831 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.13 (0.63 to 5.63) · 209 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.66 (0 to 3.39) · 25 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.59 (0.88 to 4.3) · 188 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.99 (0 to 18.96) · 26 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.72 (0.21 to 3.23) · 65 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.81 (0 to 1.84) · 1,604 cases | No different | Jul 2022 – Jun 2024 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.7 · 138 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 0.9 · 139 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -27.8 · 230 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.5 · 226 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.1 (3.2 to 8.1) · 42 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (6.9 to 14.9) · 42 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.4 · 64 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.7 (10.1 to 18.6) · 146 cases | No different | Jan 2022 – Dec 2024 |
What patients said (385 patients answered, 23% of those asked)
| Cleanliness | 5 |
| Nurse communication | 5 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 4 |
| Recommend hospital | 4 |
| Room was "always" clean | 84% |
| Nurses "always" communicated well | 84% |
| Doctors "always" communicated well | 82% |
| Staff "always" explained | 68% |
| Yes, staff "did" give patients this information | 90% |
| Yes, staff "did" give patients information about help after discharge | 90% |
| Doctors "always" explained things so they could understand | 79% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 88% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 81% |
| Nurses "always" explained things so they could understand | 80% |
| Nurses "always" listened carefully | 82% |
| Nurses "always" treated them with courtesy and respect | 91% |
| "Always" quiet at night | 61% |
| "YES", patients would definitely recommend the hospital | 77% |
| Staff "always" explained possible side effects | 54% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$262,318
Medicare paid this office $262,318 for 840 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Removal of noncancer thickened skin growth, 2-4 growths | 335 | $45,985 | $56 |
| Destruction of skin growth, 1-14 growths | 207 | $37,948 | $83 |
| Short return visit (20+ min) | 338 | $35,007 | $67 |
| Removal of fingernails or toenails, 6 or more nails | 399 | $31,690 | $33 |
| Removal of skin and tissue, 20.0 sq cm or less | 56 | $18,428 | $102 |
See all 23 services
| Removal of noncancer thickened skin growth, 2-4 growths | 335 | $45,985 | $56 |
| Destruction of skin growth, 1-14 growths | 207 | $37,948 | $83 |
| Short return visit (20+ min) | 338 | $35,007 | $67 |
| Removal of fingernails or toenails, 6 or more nails | 399 | $31,690 | $33 |
| Removal of skin and tissue, 20.0 sq cm or less | 56 | $18,428 | $102 |
| New patient visit (30+ min) | 222 | $16,901 | $76 |
| New patient visit (45+ min) | 71 | $7,611 | $107 |
| Return visit (30+ min) | 65 | $7,445 | $95 |
| Removal of noncancer thickened skin growth, 1 growth | 56 | $5,852 | $44 |
| Correction of toe joint deformity | 14 | $4,245 | $177 |
| Permanent removal fingernail or toenail | 26 | $3,966 | $107 |
| Injection of anesthetic and/or steroid drug into foot nerve | 36 | $2,654 | $39 |
| X-ray of foot, minimum of 3 views | 50 | $2,444 | $29 |
| Removal of tissue from wound, 20.0 sq cm or less | 13 | $2,190 | $78 |
| Incision of joint capsule of foot and toe | 11 | $2,176 | $136 |
| Injection into tendon or ligament | 34 | $1,784 | $34 |
| Simple or single drainage of skin abscess | 19 | $1,777 | $89 |
| Simple separation of fingernail or toenail from nail bed, first nail | 18 | $1,591 | $88 |
| Aspiration and/or injection of fluid from medium joint | 25 | $1,238 | $34 |
| Removal of fingernails or toenails, 1-5 nails | 16 | $923 | $27 |
| Aspiration and/or injection of fluid from small joint | 11 | $458 | $38 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 67 | $92 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 25 | $3 | None |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 1-10 | None |
| Removal of nail tissue | 938 | More than 91% of doctors who do this |
| Removal of skin lesions | 374 | More than 84% of doctors who do this |
| Removal of tissue | 222 | More than 92% of doctors who do this |
| Removal or shaving of skin growth | 893 | More than 98% of doctors who do this |
Procedures year by year
| Procedure | 2023 | 2024 |
|---|---|---|
| Removal of fingernails or toenails, 6 or more nails | 504 | 950 |
| Removal of noncancer thickened skin growth, 2-4 growths | 376 | 818 |
| Destruction of skin growth, 1-14 growths | 224 | 456 |
| Removal of skin and tissue, 20.0 sq cm or less | 96 | 181 |
| Removal of noncancer thickened skin growth, 1 growth | 87 | 133 |
| Injection of anesthetic and/or steroid drug into foot nerve | 15 | 68 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
840 Original Medicare patients in 2024. Average age 77 · Under 65 7% · 85 and older 24% · Women 56% · Also on Medicaid 22% · Health risk score 1.39. At or below the middle of the specialty; the typical podiatry clinician is at 1.55.
Conditions among them: High blood pressure 75% · Diabetes 40% · Chronic kidney disease 27% · Coronary heart disease 26% · Atrial fibrillation 22% · Depression 19% · Heart failure 18% · COPD 18% · Cancer 13% · Dementia 10% · Stroke 7%.
The office billed $432,050, Medicare allowed $359,010 and paid $262,318; for 4,166 services of 76 kinds; $95 of it was for drugs given in the office and $262,222 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 840 | 4,166 | 77 | 1.39 | $432,050 | $262,318 |
| 2023 | 674 | 2,135 | 76 | 1.39 | $216,804 | $146,305 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 19 services
| Removal of noncancer thickened skin growth, 2-4 growths | 275 | $23,191 | $62 |
| Destruction of skin growth, 1-14 growths | 138 | $21,071 | $94 |
| Short return visit (20+ min) | 217 | $20,193 | $71 |
| Removal of fingernails or toenails, 6 or more nails | 356 | $18,210 | $36 |
| New patient visit (30+ min) | 176 | $15,264 | $87 |
| Removal of skin and tissue, 20.0 sq cm or less | 34 | $10,247 | $107 |
| New patient visit (45+ min) | 38 | $4,709 | $124 |
| Removal of noncancer thickened skin growth, 1 growth | 70 | $4,398 | $51 |
| Return visit (30+ min) | 38 | $4,325 | $103 |
| Permanent removal fingernail or toenail | 27 | $3,811 | $123 |
| Removal of tissue from wound, 20.0 sq cm or less | 13 | $1,770 | $84 |
| Simple or single drainage of skin abscess | 14 | $1,408 | $101 |
| Aspiration and/or injection of fluid from medium joint | 18 | $865 | $35 |
| Injection into tendon or ligament | 15 | $616 | $38 |
| Injection of anesthetic and/or steroid drug into foot nerve | 13 | $587 | $39 |
| Aspiration and/or injection of fluid from small joint | 11 | $497 | $38 |
| Removal of fingernails or toenails, 1-5 nails | 12 | $379 | $27 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 34 | $36 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 30 | $4 | None |
Medicaid work
$22,095 in 2024
Medicaid paid $22,095 for 651 billed services this clinician did in 2024, up to 41 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions | 114 | $7,680 |
| Short return visit (20+ min) | 315 | $6,489 |
| New patient visit (30+ min) | 109 | $5,424 |
| REMOVAL OF NAIL BED | 13 | $1,208 |
| Paring or cutting of benign hyperkeratotic lesion (eg, corn or callus); 2 to 4 lesions | 71 | $807 |
| Debridement of nail(s) by any method(s); 6 or more | 29 | $487 |
| 2024 | 651 | 6 | 41 | $22,095 |
| 2023 | 358 | 6 | 38 | $9,377 |
See the largest Medicaid services in earlier years
2023
| New patient visit (30+ min) | 85 | $3,939 |
| Short return visit (20+ min) | 147 | $3,099 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions | 17 | $832 |
| Debridement of nail(s) by any method(s); 6 or more | 37 | $696 |
| Paring or cutting of benign hyperkeratotic lesion (eg, corn or callus); 2 to 4 lesions | 60 | $475 |
| Return visit (30+ min) | 12 | $338 |
Drugs they prescribed that Part D paid
$14,688
Pharmacies billed $14,688 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 13% of their Part D prescriptions (57 of 434) in 2024. Above the middle of the specialty; the typical podiatry clinician is at 5%.
422 generic and 12 brand-name prescriptions · $14,688 in drug cost · 74 antibiotic prescriptions to 61 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ketoconazole | 45 | $1,046 | $23 |
| Terbinafine | 51 | $674 | $13 |
| Clotrimazole-Betamethasone | 24 | $528 | $22 |
| Oxycodone-Acetaminophen | 27 | $299 | $11 |
| Gabapentin | 60 | $255 | $4 |
See all 14 drugs
| Ketoconazole | 45 | $1,046 | $23 |
| Terbinafine | 51 | $674 | $13 |
| Clotrimazole-Betamethasone | 24 | $528 | $22 |
| Oxycodone-Acetaminophen | 27 | $299 | $11 |
| Gabapentin | 60 | $255 | $4 |
| Methylprednisolone | 38 | $237 | $6 |
| Cefadroxil | 31 | $235 | $8 |
| Pregabalin | 13 | $147 | $11 |
| Hydrocodone-Acetaminophen | 16 | $147 | $9 |
| Diclofenac | 11 | $134 | $12 |
| Amoxicillin-Clavulanate Potass | 17 | $110 | $6 |
| Clindamycin | 17 | $78 | $5 |
| Meloxicam | 30 | $52 | $2 |
| Tramadol | 11 | $19 | $2 |
Year by year
| 2024 | 434 | 229 | 13% (57) | 3% | $14,688 |
| 2023 | 186 | 118 | 9% (17) | None | $4,581 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Ketoconazole | 28 | $521 | $19 |
| Cefadroxil | 14 | $169 | $12 |
| Methylprednisolone | 13 | $120 | $9 |
| Meloxicam | 27 | $93 | $3 |
Money from drug and device companies
$4,229 in 2025
| 2025 | 7 | 36 | None | $4,229 |
| 2024 | 9 | 76 | None | $7,225 |
| 2023 | 8 | 37 | None | $1,084 |
| 2022 | 6 | 28 | None | $2,482 |
| 2021 | 4 | 8 | None | $2,629 |
| 2020 | 1 | 1 | None | $1,658 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Stryker | Prostep | $2,490 | 18 payments
|
| Paragon 28 | Portfolio | $1,063 | 5 payments
|
| Treace Medical Concepts | Tmc Nanoplasty System | $497 | 2 payments
|
| DePuy Synthes Sales | Motoband | $102 | 2 payments
|
| Globus Medical | Senza | $32 | 1 payment
|
| Ortho Dermatologics a division of Bausch Health US | Jublia | $24 | 1 payment
|
See all 30 published payments
| Treace Medical Concepts | Travel · 2025-10-19 | Tmc Nanoplasty System | $474 |
| Stryker | Meals · 2025-10-18 | Prostep Mica | $98 |
| Stryker | Travel · 2025-10-18 | Prostep | $586 |
| Stryker | Meals · 2025-10-18 | Prostep | $29 |
| Stryker | Meals · 2025-10-18 | Prostep | $29 |
| Stryker | Meals · 2025-10-17 | Prostep | $173 |
| Stryker | Travel · 2025-10-17 | Prostep | $81 |
| Stryker | Travel · 2025-10-17 | Prostep | $293 |
| Stryker | Travel · 2025-10-17 | Prostep | $81 |
| Globus Medical | Meals · 2025-09-22 | Senza | $32 |
| Stryker | Meals · 2025-09-10 | Prostep Mica | $67 |
| Stryker | Travel · 2025-09-10 | Prostep | $536 |
| Paragon 28 | Meals · 2025-08-29 | Portfolio | $39 |
| Stryker | Meals · 2025-08-07 | Actishield | $31 |
| Stryker | Meals · 2025-07-24 | Augment Injectable | $7 |
| Ortho Dermatologics a division of Bausch Health US | Meals · 2025-06-30 | Jublia | $24 |
| Stryker | Meals · 2025-06-25 | Ortholoc 2 Lapifuse | $12 |
| Treace Medical Concepts | Meals · 2025-06-17 | Tmc Nanoplasty System | $23 |
| Stryker | Meals · 2025-04-24 | Allomatrix | $92 |
| Stryker | Meals · 2025-03-29 | Augment Injectable | $92 |
| DePuy Synthes Sales | Meals · 2025-03-28 | Motoband | $73 |
| DePuy Synthes Sales | Meals · 2025-03-28 | Motoband | $28 |
| Stryker | Meals · 2025-03-27 | Augment Injectable | $63 |
| Stryker | Meals · 2025-03-19 | Prostep Mica | $79 |
| Paragon 28 | Meals · 2025-02-07 | Portfolio | $195 |
| Paragon 28 | Travel · 2025-02-07 | Portfolio | $386 |
| Paragon 28 | Travel · 2025-02-07 | Portfolio | $27 |
| Stryker | Meals · 2025-01-28 | Pangea | $141 |
| Smith+Nephew | Meals · 2025-01-21 | Stravix | $22 |
| Paragon 28 | Travel · 2025-01-10 | Apex 3d | $417 |
See earlier years (2024, 2023, 2022, 2021, 2020)
2024: $7,225
| Stryker | Inbone | $3,686 | 32 payments
|
| Paragon 28 | Hammertube Sterile Implant Kits | $1,543 | 8 payments
|
| Arthrex | None | $1,078 | 13 payments
|
| Cornerstone Medical Associates | None | $438 | 2 payments
|
| Treace Medical Concepts | Lapiplasty System | $179 | 5 payments
|
| Biotissue Holdings | None | $160 | 5 payments
|
| International Life Sciences | Flexband | $84 | 1 payment
|
| Abbvie | Teflaro | $29 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $28 | 1 payment
|
2023: $1,084
| Stryker | Augment Injectable | $390 | 9 payments
|
| Kerecis | Kerecis Omega3 Surgiclose | $219 | 1 payment
|
| International Life Sciences | None | $218 | 1 payment
|
| Treace Medical Concepts | Lapiplasty System | $144 | 3 payments
|
| Smith+Nephew | Grafix Pl | $40 | 2 payments
|
| Paragon 28 | Ttc Nail | $29 | 1 payment
|
| Medline Industries Lp | None | $29 | 1 payment
|
| Elite Orthopedics | None | $16 | 1 payment
|
2022: $2,482
| Elite Orthopedics | None | $1,239 | 3 payments
|
| Paragon 28 | Product Portfolio | $538 | 3 payments
|
| Stryker | Augment Injectable | $420 | 5 payments
|
| Smith+Nephew | Versajet | $121 | 1 payment
|
| Integra LifeSciences | Integra | $120 | 1 payment
|
| Kerecis | Kerecis Omega3 Surgiclose | $43 | 1 payment
|
2021: $2,629
| Elite Orthopedics | None | $2,428 | 4 payments
|
| Integra LifeSciences | Integra Meshed Bilayer Wound Matrix | $145 | 1 payment
|
| Melinta Therapeutics | Kimyrsa | $39 | 2 payments
|
| Kci USA | Prevena | $17 | 1 payment
|
2020: $1,658
| Elite Orthopedics | None | $1,658 | 1 payment
|
Professional record
- NPI
- 1407417744
- Licence
- CA E5929
- Trained
- California School of Podiatric Medicine, 2020 · 6 years ago
- Group
- Lodi Podiatry Group
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 213ES0103X (213ES0103X)
- Mailing address
- 12303 De Paul Dr, Bridgeton, MO, 63044
- NPI first listed
- 2019-06-26
- NPI last updated
- 2023-07-27
- NPI record certified
- 2023-07-27
This is when the NPI record was last certified, not a medical board exam.